Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Doctors holding up puzzle pieces

Developing Standardized Reporting Templates for Sarcomas: Insights from Prof. Dr. Wolfgang Kunz

Sarcomas are a rare and heterogeneous group of malignant tumors that pose significant challenges in both diagnosis and treatment. Within the framework…

The image shows Prof. Dr. Wolfgang Kunz from LMU Munich, one of the universities involved in the BORN project

Standardized Reporting Template for Sarcomas in the BZKF BORN-Project: Interview with Prof. Dr. Wolfgang Kunz of LMU Munich

Sarcomas are a rare and highly diverse group of malignant tumors that affect both soft tissue and bones, posing significant challenges due to their…

Image of a Uterus

RACOON FADEN Project Tackles Early Detection of Adenomyosis

Endometriosis is a vastly under-researched condition affecting women, but it is finally receiving the attention it deserves through the RACOON FADEN…